{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:52:20Z","timestamp":1784829140606,"version":"3.55.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology of Taiwan","doi-asserted-by":"publisher","award":["NSC 106-2311-B-006-008-MY2"],"award-info":[{"award-number":["NSC 106-2311-B-006-008-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology of Taiwan","doi-asserted-by":"publisher","award":["NSC 106-2320-B-006-024"],"award-info":[{"award-number":["NSC 106-2320-B-006-024"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic kidney disease and its complications are a major public health problem worldwide. Diabetic nephropathy has become the main contributing cause of terminal renal failure. There are now evidences that different inflammatory molecules, including proinflammatory cytokines, play a critical role in the development of microvascular diabetic complications, including nephropathy. IL-20 is emerging as a potent angiogenic, chemotactic, and proinflammatory cytokine related to several chronic inflammatory disorders likes psoriasis, atherosclerosis, and renal failure. This review discusses the role of IL-20 as a pathogenic factor in renal injury, focusing on chronic kidney disease and diabetic nephropathy, and describes potential treatment strategies based on modulation of IL-20's function.<\/jats:p>\n               <jats:p>IL-20 is a crucial mediator for regulating tubular cell apoptosis, promoting renal fibrosis, and enhancing podocyte dysfunction.<\/jats:p>","DOI":"10.1002\/jlb.mr1217-489r","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T13:59:02Z","timestamp":1531403942000},"page":"919-923","source":"Crossref","is-referenced-by-count":18,"title":["The role of IL-20 in chronic kidney disease and diabetic nephropathy: Pathogenic and therapeutic implications"],"prefix":"10.1093","volume":"104","author":[{"given":"Ming-Shi","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University , Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsiang","family":"Hsu","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, College of Medicine, National Cheng Kung University , Tainan, Taiwan"},{"name":"Clinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University , Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"2023032406062164300_jlb10188-cit-0001","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on \u2018KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease\u2019","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"key":"2023032406062164300_jlb10188-cit-0002","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrneph.2017.52","article-title":"The systemic nature of CKD","volume":"13","author":"Zoccali","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2023032406062164300_jlb10188-cit-0003","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5527\/wjn.v4.i1.57","article-title":"Biomarkers in chronic kidney disease, from kidney function to kidney damage","volume":"4","author":"Lopez-Giacoman","year":"2015","journal-title":"World J Nephrol"},{"key":"2023032406062164300_jlb10188-cit-0004","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2023032406062164300_jlb10188-cit-0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1053\/j.ackd.2005.07.011","article-title":"Progression in chronic kidney disease","volume":"12","author":"Eddy","year":"2005","journal-title":"Adv Chronic Kidney Dis"},{"key":"2023032406062164300_jlb10188-cit-0006","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0002-9440(10)62503-5","article-title":"Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease","volume":"159","author":"Stahl","year":"2001","journal-title":"Am J Pathol"},{"key":"2023032406062164300_jlb10188-cit-0007","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ndt\/gfu411","article-title":"Diabetic nephropathy: landmark clinical trials and tribulations","volume":"31","author":"Chan","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2023032406062164300_jlb10188-cit-0008","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/CS20120198","article-title":"Inflammation and the pathogenesis of diabetic nephropathy","volume":"124","author":"Wada","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"2023032406062164300_jlb10188-cit-0009","doi-asserted-by":"crossref","first-page":"948417","DOI":"10.1155\/2015\/948417","article-title":"Inflammatory cytokines in diabetic nephropathy","volume":"2015","author":"Donate-Correa","year":"2015","journal-title":"J Diabetes Res"},{"key":"2023032406062164300_jlb10188-cit-0010","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1681\/ASN.2005040393","article-title":"Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease","volume":"16","author":"Tuttle","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2023032406062164300_jlb10188-cit-0011","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11892-006-0080-1","article-title":"Inflammation and diabetic nephropathy","volume":"6","author":"Mora","year":"2006","journal-title":"Curr Diab Rep"},{"key":"2023032406062164300_jlb10188-cit-0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000060147","article-title":"Role of macrophages in the pathogenesis of diabetic nephropathy","author":"Shikata","year":"2001","journal-title":"Contrib Nephrol"},{"key":"2023032406062164300_jlb10188-cit-0013","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2005080859","article-title":"Leukocyte recruitment and vascular injury in diabetic nephropathy","volume":"17","author":"Galkina","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2023032406062164300_jlb10188-cit-0014","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","author":"Liu","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2023032406062164300_jlb10188-cit-0015","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2004070612","article-title":"Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db\/db mice","volume":"16","author":"Chow","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2023032406062164300_jlb10188-cit-0016","doi-asserted-by":"crossref","first-page":"F1358","DOI":"10.1152\/ajprenal.00332.2011","article-title":"Monocyte\/macrophage chemokine receptor CCR2 mediates diabetic renal injury","volume":"301","author":"Awad","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023032406062164300_jlb10188-cit-0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0092-8674(01)00187-8","article-title":"Interleukin 20: discovery, receptor identification, and role in epidermal function","volume":"104","author":"Blumberg","year":"2001","journal-title":"Cell"},{"key":"2023032406062164300_jlb10188-cit-0018","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2008.08890.x","article-title":"Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model","volume":"160","author":"Stenderup","year":"2009","journal-title":"Br J Dermatol"},{"key":"2023032406062164300_jlb10188-cit-0019","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1161\/01.ATV.0000232502.88144.6f","article-title":"IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice","volume":"26","author":"Chen","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023032406062164300_jlb10188-cit-0020","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.4049\/jimmunol.0803653","article-title":"IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke","volume":"182","author":"Chen","year":"2009","journal-title":"J Immunol"},{"key":"2023032406062164300_jlb10188-cit-0021","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.gene.6364291","article-title":"Interleukin-20 promotes angiogenesis in a direct and indirect manner","volume":"7","author":"Hsieh","year":"2006","journal-title":"Genes Immun"},{"key":"2023032406062164300_jlb10188-cit-0022","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.3390\/ijms14046720","article-title":"Cytokines and the skin barrier","volume":"14","author":"Hanel","year":"2013","journal-title":"Int J Mol Sci"},{"key":"2023032406062164300_jlb10188-cit-0023","doi-asserted-by":"crossref","first-page":"24339","DOI":"10.1038\/srep24339","article-title":"Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis","volume":"6","author":"Hsu","year":"2016","journal-title":"Sci Rep"},{"key":"2023032406062164300_jlb10188-cit-0024","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20102234","article-title":"Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss","volume":"208","author":"Hsu","year":"2011","journal-title":"J Exp Med"},{"key":"2023032406062164300_jlb10188-cit-0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/14728222.2011.534461","article-title":"IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases","volume":"15","author":"Leng","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"2023032406062164300_jlb10188-cit-0026","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2006.07.006","article-title":"Tissue microarray analysis of interleukin-20 expression","volume":"35","author":"Hsing","year":"2006","journal-title":"Cytokine"},{"key":"2023032406062164300_jlb10188-cit-0027","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/art.22039","article-title":"Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis","volume":"54","author":"Hsu","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023032406062164300_jlb10188-cit-0028","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1541-7786.MCR-12-0276","article-title":"Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth","volume":"10","author":"Hsu","year":"2012","journal-title":"Mol Cancer Res"},{"key":"2023032406062164300_jlb10188-cit-0029","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4049\/jimmunol.1102843","article-title":"Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models","volume":"188","author":"Hsu","year":"2012","journal-title":"J Immunol"},{"key":"2023032406062164300_jlb10188-cit-0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cytogfr.2010.08.001","article-title":"IL-20: biological functions mediated through two types of receptor complexes","volume":"21","author":"Wegenka","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"2023032406062164300_jlb10188-cit-0031","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1196\/annals.1423.039","article-title":"Interleukin-20 as a target in psoriasis treatment","volume":"1110","author":"Stenderup","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2023032406062164300_jlb10188-cit-0032","doi-asserted-by":"crossref","first-page":"R531","DOI":"10.1016\/S0960-9822(01)00312-8","article-title":"Cytokines: IL-20 - a new effector in skin inflammation","volume":"11","author":"Rich","year":"2001","journal-title":"Curr Biol"},{"key":"2023032406062164300_jlb10188-cit-0033","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/gene.2008.28","article-title":"Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure","volume":"9","author":"Li","year":"2008","journal-title":"Genes Immun"},{"key":"2023032406062164300_jlb10188-cit-0034","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1097\/BRS.0b013e31817eb872","article-title":"IL-20 may contribute to the pathogenesis of human intervertebral disc herniation","volume":"33","author":"Huang","year":"2008","journal-title":"Spine (Phila Pa 1976)"},{"key":"2023032406062164300_jlb10188-cit-0035","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.4049\/jimmunol.170.6.3369","article-title":"IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis","volume":"170","author":"Li","year":"2003","journal-title":"J Immunol"},{"key":"2023032406062164300_jlb10188-cit-0036","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.bbrc.2008.07.039","article-title":"Interleukin-20 targets renal cells and is associated with chronic kidney disease","volume":"374","author":"Wei","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"2023032406062164300_jlb10188-cit-0037","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2008.07.006","article-title":"Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis","volume":"129","author":"Li","year":"2008","journal-title":"Clin Immunol"},{"key":"2023032406062164300_jlb10188-cit-0038","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ki.2010.516","article-title":"Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases","volume":"79","author":"Barnes","year":"2011","journal-title":"Kidney Int"},{"key":"2023032406062164300_jlb10188-cit-0039","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/ars.2016.6664","article-title":"Diabetes and kidney disease: role of oxidative stress","volume":"25","author":"Jha","year":"2016","journal-title":"Antioxid Redox Signal"},{"key":"2023032406062164300_jlb10188-cit-0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/ki.1994.122","article-title":"Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis","volume":"45","author":"Yamamoto","year":"1994","journal-title":"Kidney Int"},{"key":"2023032406062164300_jlb10188-cit-0041","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/emm.2016.169","article-title":"Interleukin-20 targets podocytes and is upregulated in experimental murine diabetic nephropathy","volume":"49","author":"Hsu","year":"2017","journal-title":"Exp Mol Med"},{"key":"2023032406062164300_jlb10188-cit-0042","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2337\/diabetes.55.01.06.db05-0894","article-title":"Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy","volume":"55","author":"Susztak","year":"2006","journal-title":"Diabetes"},{"key":"2023032406062164300_jlb10188-cit-0043","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000368940","article-title":"Update on inflammation in chronic kidney disease","volume":"39","author":"Akchurin","year":"2015","journal-title":"Blood Purif"},{"key":"2023032406062164300_jlb10188-cit-0044","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.tips.2004.02.011","article-title":"Historical review: cytokines as therapeutics and targets of therapeutics","volume":"25","author":"Vilcek","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"2023032406062164300_jlb10188-cit-0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation, and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int Anesthesiol Clin"},{"key":"2023032406062164300_jlb10188-cit-0046","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1172\/JCI37346","article-title":"Many cytokines are very useful therapeutic targets in disease","volume":"118","author":"Feldmann","year":"2008","journal-title":"J Clin Invest"},{"key":"2023032406062164300_jlb10188-cit-0047","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","article-title":"Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease","volume":"1843","author":"Turner","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"2023032406062164300_jlb10188-cit-0048","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"2023032406062164300_jlb10188-cit-0049","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1378\/chest.118.2.503","article-title":"Proinflammatory cytokines","volume":"118","author":"Dinarello","year":"2000","journal-title":"Chest"},{"key":"2023032406062164300_jlb10188-cit-0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3727\/096368914X678319","article-title":"The therapeutic potential of anti-interleukin-20 monoclonal antibody","volume":"23","author":"Hsu","year":"2014","journal-title":"Cell transplantation"},{"key":"2023032406062164300_jlb10188-cit-0051","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/art.39083","article-title":"Efficacy and safety of anti-interleukin-20 monoclonal antibody in patients with rheumatoid arthritis: a randomized phase IIa trial","volume":"67","author":"Senolt","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2FJLB.MR1217-489R","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/104\/5\/919\/49558040\/jlb10188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/104\/5\/919\/49558040\/jlb10188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T06:07:03Z","timestamp":1679638023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/104\/5\/919\/6935397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,7,12]]},"published-print":{"date-parts":[[2018,10,19]]}},"URL":"https:\/\/doi.org\/10.1002\/jlb.mr1217-489r","relation":{},"ISSN":["1938-3673","0741-5400"],"issn-type":[{"value":"1938-3673","type":"electronic"},{"value":"0741-5400","type":"print"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,7,12]]}}}